blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

Latvia joins the Federated Register
Click here for more information on the Federated Register.

2025-04-16

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2561069

EP2561069 - LYSOSOMAL STORAGE DISEASE ENZYME [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  12.01.2018
Database last updated on 26.04.2025
FormerThe patent has been granted
Status updated on  03.02.2017
FormerGrant of patent is intended
Status updated on  25.01.2017
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 12.08.2020  [2020/33]
Applicant(s)For all designated states
Alexion Pharmaceuticals, Inc.
100 College Street
New Haven, CT 06510 / US
[2017/07]
Former [2015/21]For all designated states
Synageva BioPharma Corp.
33 Hayden Avenue
Lexington, MA 02421 / US
Former [2013/09]For all designated states
Synageva BioPharma Corp.
128 Spring Street, Suite 520
Lexington, MA 02421 / US
Inventor(s)01 / QUINN, Anthony
107 Manet Road
Chestnut Hill Massachusetts 02467 / US
02 / HARVEY, Alex J.
106 Fox Trace
Athens Georgia 30606 / US
 [2013/09]
Representative(s)Mathys & Squire
The Shard
32 London Bridge Street
London SE1 9SG / GB
[N/P]
Former [2017/10]Mathys & Squire LLP
The Shard
32 London Bridge Street
London SE1 9SG / GB
Former [2013/09]Mathys & Squire LLP
120 Holborn London
EC1N 2SQ / GB
Application number, filing date11772834.523.04.2011
[2017/10]
WO2011US33699
Priority number, dateUS20110432372P13.01.2011         Original published format: US 432372 P
US20100456014P29.10.2010         Original published format: US 456014 P
US20100403011P09.09.2010         Original published format: US 403011 P
US20100396376P26.05.2010         Original published format: US 396376 P
US20100343177P23.04.2010         Original published format: US 343177 P
[2013/09]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2011133960
Date:27.10.2011
Language:EN
[2011/43]
Type: A2 Application without search report 
No.:EP2561069
Date:27.02.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 27.10.2011 takes the place of the publication of the European patent application.
[2013/09]
Type: B1 Patent specification 
No.:EP2561069
Date:08.03.2017
Language:EN
[2017/10]
Search report(s)International search report - published on:KR12.07.2012
(Supplementary) European search report - dispatched on:EP24.02.2014
ClassificationIPC:A61K38/46, A61K31/366, A61K31/397, A61K31/135, A61P3/06, A01K67/027, A61K31/194, C12N9/20, A61K38/38
[2014/13]
CPC:
C12N9/20 (EP,IL,KR,RU,US); A61K35/00 (RU); A01K67/0278 (EP,IL,KR,US);
A61K31/194 (EP,IL,KR,US); A61K38/385 (IL,KR,US); A61K38/465 (EP,IL,KR,US);
A61P1/00 (EP); A61P1/16 (EP); A61P3/00 (EP);
A61P3/06 (EP); A61P35/04 (EP); A61P43/00 (EP);
A61P9/00 (EP); C12N15/86 (EP); C12Y301/01013 (EP,IL,KR,US);
A01K2217/052 (EP,IL,KR,US); A01K2227/30 (EP,IL,KR,US); A01K2267/01 (EP,IL,KR,US);
C12N2740/10041 (IL,KR,US); C12N2740/11043 (EP); C12N2740/11045 (EP);
C12N2760/20222 (EP) (-)
Former IPC [2013/09]C12N9/20, C12N15/55, A61K38/46
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/09]
Extension statesBA20.11.2012
ME20.11.2012
TitleGerman:ENZYM FÜR DIE LYSOSOMALE SPEICHERKRANKHEIT[2013/09]
English:LYSOSOMAL STORAGE DISEASE ENZYME[2013/09]
French:ENZYME DES MALADIES LYSOSOMALES[2013/09]
Entry into regional phase20.11.2012National basic fee paid 
20.11.2012Search fee paid 
20.11.2012Designation fee(s) paid 
20.11.2012Examination fee paid 
Examination procedure20.11.2012Examination requested  [2013/09]
23.09.2014Amendment by applicant (claims and/or description)
28.05.2015Despatch of a communication from the examining division (Time limit: M04)
07.10.2015Reply to a communication from the examining division
18.03.2016Communication of intention to grant the patent
28.07.2016Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
15.09.2016Communication of intention to grant the patent
24.01.2017Fee for grant paid
24.01.2017Fee for publishing/printing paid
24.01.2017Receipt of the translation of the claim(s)
Divisional application(s)EP17158770.2  / EP3205351
EP23159801.2
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  28.05.2015
Opposition(s)11.12.2017No opposition filed within time limit [2018/07]
Fees paidRenewal fee
12.04.2013Renewal fee patent year 03
25.03.2014Renewal fee patent year 04
10.04.2015Renewal fee patent year 05
27.04.2016Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL08.03.2017
CY08.03.2017
EE08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
MC08.03.2017
MK08.03.2017
RS08.03.2017
SM08.03.2017
LU23.04.2017
MT23.04.2017
BG08.06.2017
IS08.07.2017
[2020/33]
Former [2019/51]CY08.03.2017
EE08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
MC08.03.2017
MK08.03.2017
RS08.03.2017
SM08.03.2017
LU23.04.2017
MT23.04.2017
BG08.06.2017
IS08.07.2017
Former [2019/46]CY08.03.2017
EE08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
MC08.03.2017
RS08.03.2017
SM08.03.2017
LU23.04.2017
MT23.04.2017
BG08.06.2017
IS08.07.2017
Former [2018/43]EE08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
MC08.03.2017
RS08.03.2017
SM08.03.2017
LU23.04.2017
MT23.04.2017
BG08.06.2017
IS08.07.2017
Former [2018/14]EE08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
MC08.03.2017
RS08.03.2017
SM08.03.2017
LU23.04.2017
BG08.06.2017
IS08.07.2017
Former [2018/06]EE08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
MC08.03.2017
RS08.03.2017
SM08.03.2017
BG08.06.2017
IS08.07.2017
Former [2017/51]EE08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
RS08.03.2017
SM08.03.2017
BG08.06.2017
IS08.07.2017
Former [2017/50]EE08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
RS08.03.2017
BG08.06.2017
IS08.07.2017
Former [2017/41]HR08.03.2017
LT08.03.2017
LV08.03.2017
RS08.03.2017
BG08.06.2017
Documents cited:Search[X]WO0156596  (CHILDREN S HOSPITAL RES FOUNDA [US]) [X] 1-13,17-19 * paragraphs [0035] , [0036] *;
 [X]US2009178147  (HARVEY ALEX J [US]) [X] 1-13,17-19 * paragraph [0151] *;
 [X]US2009297496  (GRABOWSKI GREGORY A [US]) [X] 1-13,17-19 * paragraphs [0007] , [0011] , [0040] *;
 [E]WO2012112681  (SHIRE HUMAN GENETIC THERAPIES [US], et al) [E] 1-13,17-19 * paragraphs [0014] , [0105] *;
 [X]  - IKEDA S ET AL, "Production of recombinant human lysosomal acid lipase in Schizosaccharomyces pombe: Development of a fed-batch fermentation and purification process", JOURNAL OF BIOSCIENCE AND BIOENGINEERING, ELSEVIER, AMSTERDAM, NL, (200401), vol. 98, no. 5, ISSN 1389-1723, pages 366 - 373, XP004695391 [X] 1-13,17-19 * abstract * * page 371 column 2 final paragraph to page 372 column 1 first paragraph *
International search[A]US2010062982  (HARVEY ALEX J [US]);
by applicantUS5897998
 WO0156596
 US2004223960
 US6849257
 US2007092486
 US2007264249
 US2008064862
 US7524626
 US2009178147
 US2009297496
 US2010062982
 WO2012112681
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.